Average daily dose, medication adherence, and healthcare costs among commercially-insured patients with fibromyalgia treated with duloxetine

Current Medical Research and Opinion

Volumn 27, Issue 6, 2011, Pages 1131-1139

  Wu, N ^a   Chen, S ^a   Boulanger, L ^a   Rao, P ^a   Zhao, Y ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Adherence; Duloxetine; Fibromyalgia; Healthcare costs

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; DOPAMINE RECEPTOR STIMULATING AGENT; DULOXETINE; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FIBROMYALGIA; FOLLOW UP; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY;

ADULT; ANTIDEPRESSIVE AGENTS; FEMALE; FIBROMYALGIA; HEALTH CARE COSTS; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; THIOPHENES;

EID: 79956161714     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.570744     Document Type: Article

References (24)

1. Ablin J, Neumann L, BuskilaD. Pathogenesis of fibromyalgia-a review. Joint Bone Spine 2008;75:273-9
2. Adak B, Tekeoglu I, Ediz L, et al. Fibromyalgia frequency in hepatitis B carriers. J Clin Rheumatol 2005;11:157-9 (Pubitemid 40863829)
3. Moldofsky H. The significance, assessment, and management of nonrestora-tive sleep in fibromyalgia syndrome. CNS Spectr 2008;13(3 Suppl 5):22-6 (Pubitemid 351532440)
4. Staud R, Spaeth M. Psychophysical and neurochemical abnormalities of pain processing in fibromyalgia. CNS Spectr 2008;13(3 Suppl 5):12-17 (Pubitemid 351532438)
5. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26-35
6. Neumann L, BuskilaD. Epidemiologyoffibromyalgia. CurrPain Headache Rep 2003;7:362-8
7. Peterson EL. Fibromyalgia\management of a misunderstood disorder. J Am Acad Nurse Pract 2007;19:341-8
8. Berger A, Dukes E, Martin S, et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007;61:1498-508 (Pubitemid 47228612)
9. Russell IJ, Raphael KG. Fibromyalgia syndrome: presentation, diagnosis, differential diagnosis, and vulnerability. CNS Spectr 2008;13(3 Suppl 5):6-11 (Pubitemid 351532437)
10. Bennett RM, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 2007;8:27
11. Assefi NP, Coy TV, Uslan D, et al. Financial, occupational, and personal consequences of disability in patients with chronic fatigue syndrome and fibromyalgia compared to other fatiguing conditions. J Rheumatol 2003; 30:804-8 (Pubitemid 36402776)
12. White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008;50:13-24
13. Robinson RL, Birnbaum HG, Morley MA, et al. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003;30:1318-25 (Pubitemid 36666360)
14. American Pain Society. American Pain Society releases new clinical practice guideline for fibromyalgia pain, http://www.ampainsoc.org/press/2005/ 101005.htm 2005
15. Navarro RP. Contemporary management strategies for fibromyalgia. Am J Manag Care 2009;15(7 Suppl):S197-218
16. Zhao Y, Chen S, Wu N, et al. Medication adherence and healthcare costs among fibromyalgia patients treated with duloxetine. Pain Pract 2010; Dec 29. doi: 10.1111/j.1533-2500.2010.00431.x. [Epub ahead of print]
17. Zhao Y, Sun P, Watson P, et al. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Pain Pract 2010; Aug 26. [Epub ahead of print]
18. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997: 50:105-16 (Pubitemid 27089212)
19. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996;49:1429-33 (Pubitemid 27028932)
20. Bureau of Labor Statistics. Consumer Price Index: January 2008
21. Cymbalta® [package insert]. Indianapolis, IN: Eli Lilly and Company, 2009
22. Afifi AA, Kotlerman JB, Ettner SL, et al. Methods for improving regression analysis for skewed continuous or counted responses. Annu Rev Public Health 2007;28:95-111 (Pubitemid 46833335)
23. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman & Hall, 1993
24. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl 2005;75:6-21 (Pubitemid 41113954)